Incredible piece for those with Graves
ncbi.nlm.nih.gov/pmc/articl...
Copyright © 2013 by The Endocrine Society
1. In patients on methimazole, a positive TRAb is helpful in suggesting that it is not yet time to stop the medication.
2. TRAb tests are also used in the prediction of the rare neonatal transfer of GD, with the main purpose of reassuring most women with GD who will have negative or low titer and limiting the use of intensive fetal monitoring to the few others with persistent high-titer TRAb.
3. When tested with the newer assays, TRAb are emerging as a powerful marker (if not pathogen) of GO,
4. As with many autoimmune diseases, GD is characterized by remissions and flare-ups.
5. Because Graves' hyperthyroidism has a remitting and relapsing natural history, it is not surprising that the absence of TRAb at any time in the history of 1 single patient cannot guarantee that these will not return in the distant future, no matter how accurate the assay is.
6. Given the available data, we would like to suggest that testing TRAb in Graves' patients who are euthyroid while on methimazole is very useful in distinguishing patients with active disease and positive TRAb who are euthyroid only because of TH synthesis blocking of methimazole from patients in remission with negative TRAb.
a) Patients with negative or low-titer TRAb (in remission) can discontinue methimazole depending on the circumstances. Because a prolonged remission cannot be promised based on a currently negative TRAb level, patients at high risk of negative consequences from late relapses, such as patients with paroxysmal atrial fibrillation, may be best served by ongoing antithyroid drug treatment or RAI treatment.
b) Medium- to high-titer TRAb-positive patients should be counseled that a discontinuation would almost certainly be followed by a quick return of the hyperthyroidism and should be given the choice of continuation of methimazole treatment and repeat testing at biannual or annual intervals vs definitive treatment.
7. True GD hyperthyroidism cannot occur without TRAb. GD is almost unique among autoimmune diseases, in that the most important clinical manifestation of the disease, the hyperthyroidism, is entirely dependent on, and completely recapitulated by, the interaction of an autoantibody with its autoantigen. Hence, testing for the TSHR antibody should be particularly useful in the diagnosis of GD hyperthyroidism.
8. TRAb can accurately predict short-term relapses of hyperthyroidism after a course of antithyroid drugs but are less effective in predicting long-term relapses or remissions.
9. GD affects many organ systems either by the autoimmune process or as a complication of thyrotoxicosis. Systemic involvement of GD includes the eyes (Graves' ophthalmopathy [GO]) and skin (Graves' dermopathy), whereas bones, heart, liver, and other organs are affected by the excess thyroid hormone.